SFKs involved in regulating platelet activation
Subfamily . | Src kinase . | Species . | Interacting proteins . | Substrates . | Receptor signaling regulated by SFKs . | Phenotypes of knockout mouse models . |
---|---|---|---|---|---|---|
SrcA | Src | Human26 | β3,31 GPIbα,71 SHIP-144 | β3,95 FcγRIIA,43 SHIP-144 | αIIbβ3,25,31,44 α2β1,96 α6β197 | Reduced αIlbβ3-mediated signaling and functional responses21,31 |
Mouse21,31 | GPIb-IX-V,71 PAR-1, PAR-4,6,83 TP,98 α2A99 | |||||
Yes | Human16,19 | β325 | Unknown | αIIbβ3,100 PAR-1, PAR-4101 | ||
Fyn | Human18 | GPVI,50 β3,62 PECAM-160 | FcR γ-chain,50,51 PKCδ73 | αIIbβ3,62 GPVI-FcR γ-chain,50,51 GPIb-IX-V,75 PAR-1, PAR-4,7,12 P2Y127 | Reduced unknown αIIbβ3-mediated signaling and functional responses21,62 | |
Mouse51 | Reduced GPVI-FcR γ-chain–mediated signaling and aggregation/secretion21,51 | |||||
Potentiation of PAR-4–mediated aggregation12 | ||||||
Mild bleeding diathesis62 | ||||||
Fgr | Human20 | Unknown | Unknown | αIIbβ3,21 GPVI-FcR γ-chain21 | Marginal reduction in GPVI-mediated aggregation/secretion21 | |
Mouse21 | ||||||
SrcB | Lyn | Human17 | GPVI,50 β3,25,45 GPIbα,71 PECAM-1,60 SHIP-145 | FcR γ-chain,50,51 SHIP-145 | αIIbβ3,25,31,45 GPVI-FcR γ-chain,50,51 PECAM-1,13,60 GPIb-IX-V,102 | Increased αIIbβ3-mediated spreading21,45 |
Mouse51 | PAR-1, PAR-4,7,103 P2Y12,7 Mpl57 | Delayed onset of GPVI-mediated signaling and aggregation/secretion21,51 | ||||
Recovery of GPVI-mediated signaling and enhanced aggregation/secretion at later time points21,51 | ||||||
Reduced GPIb-IX-V–mediated spreading102 | ||||||
Increased megakaryopoiesis and Mpl signaling57 | ||||||
Cholesterol sensor in megakaryocyte progenitors58 | ||||||
Hck | Human60 | Unknown | ||||
Lck | Human19,20 | |||||
Blk | Not detected21 | |||||
Src-related kinases | Frk | Unknown | ||||
Brk | Unknown | |||||
Srm | Unknown |
Subfamily . | Src kinase . | Species . | Interacting proteins . | Substrates . | Receptor signaling regulated by SFKs . | Phenotypes of knockout mouse models . |
---|---|---|---|---|---|---|
SrcA | Src | Human26 | β3,31 GPIbα,71 SHIP-144 | β3,95 FcγRIIA,43 SHIP-144 | αIIbβ3,25,31,44 α2β1,96 α6β197 | Reduced αIlbβ3-mediated signaling and functional responses21,31 |
Mouse21,31 | GPIb-IX-V,71 PAR-1, PAR-4,6,83 TP,98 α2A99 | |||||
Yes | Human16,19 | β325 | Unknown | αIIbβ3,100 PAR-1, PAR-4101 | ||
Fyn | Human18 | GPVI,50 β3,62 PECAM-160 | FcR γ-chain,50,51 PKCδ73 | αIIbβ3,62 GPVI-FcR γ-chain,50,51 GPIb-IX-V,75 PAR-1, PAR-4,7,12 P2Y127 | Reduced unknown αIIbβ3-mediated signaling and functional responses21,62 | |
Mouse51 | Reduced GPVI-FcR γ-chain–mediated signaling and aggregation/secretion21,51 | |||||
Potentiation of PAR-4–mediated aggregation12 | ||||||
Mild bleeding diathesis62 | ||||||
Fgr | Human20 | Unknown | Unknown | αIIbβ3,21 GPVI-FcR γ-chain21 | Marginal reduction in GPVI-mediated aggregation/secretion21 | |
Mouse21 | ||||||
SrcB | Lyn | Human17 | GPVI,50 β3,25,45 GPIbα,71 PECAM-1,60 SHIP-145 | FcR γ-chain,50,51 SHIP-145 | αIIbβ3,25,31,45 GPVI-FcR γ-chain,50,51 PECAM-1,13,60 GPIb-IX-V,102 | Increased αIIbβ3-mediated spreading21,45 |
Mouse51 | PAR-1, PAR-4,7,103 P2Y12,7 Mpl57 | Delayed onset of GPVI-mediated signaling and aggregation/secretion21,51 | ||||
Recovery of GPVI-mediated signaling and enhanced aggregation/secretion at later time points21,51 | ||||||
Reduced GPIb-IX-V–mediated spreading102 | ||||||
Increased megakaryopoiesis and Mpl signaling57 | ||||||
Cholesterol sensor in megakaryocyte progenitors58 | ||||||
Hck | Human60 | Unknown | ||||
Lck | Human19,20 | |||||
Blk | Not detected21 | |||||
Src-related kinases | Frk | Unknown | ||||
Brk | Unknown | |||||
Srm | Unknown |